ABSTRACT
The discovery that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which causes a parkinsonian syndrome in humans, nonhuman primates, and mice (1,2), acts through inhibition of complex I of the mitochondrial electron transport chain (ETC) (3,4) stimulated investigation of a possible role for mitochondrial dysfunction in Parkinson’s disease (PD) (5).
